New Website Details Abuse Allegations Against German Psychedelic Practitioners
A new website — whoisjoeschraube.com — alleges that Joe Schraube and Miguel Delgado have taken advantage of positions of power and abused people under the influence of psychedelics.
New Website Details Abuse Allegations Against German Psychedelic Practitioners
A new website — whoisjoeschraube.com — alleges that Joe Schraube and Miguel Delgado have taken advantage of positions of power and abused people under the influence of psychedelics.
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Power Tripping offers an inside look at Psymposia and New York Magazine’s podcast “Cover Story: Power Trip.” Join the co-creators and the rest of the Psymposia team for deep dives into the histories, characters, and events that shaped our investigation.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Listen on Spotify, Apple Podcasts, or wherever podcasts are available.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Featured Stories
MAPS Canada’s Data Breach Foreshadows Corporadelic Future
As the psychedelic pharmaceutical industry increasingly prioritizes personal data extraction through mobile apps, wearables, and so-called “targeted” medicine, a recent data breach by former MAPS Canada Executive Director Mark Haden provides a warning about some of the possible consequences to the financial incentives of datafication.
Featured Stories
MAPS Canada’s Data Breach Foreshadows Corporadelic Future
As the psychedelic pharmaceutical industry increasingly prioritizes personal data extraction through mobile apps, wearables, and so-called “targeted” medicine, a recent data breach by former MAPS Canada Executive Director Mark Haden provides a warning about some of the possible consequences to the financial incentives of datafication.
DoubleBlind Claims Its Ad Was the ‘First-Ever’ U.S. Psychedelic Destigmatization Campaign — It Wasn’t
DoubleBlind claims its recently-unveiled New York City billboard is a lot of things, except what it actually is: a giant advertisement.
Hamilton Morris Hired by Psilocybin Startup COMPASS Pathways, Ends “Hamilton’s Pharmacopeia” On Vice
by Russell Hausfeld , David Nickles
Hamilton Morris, the creator of Vice’s “Hamilton’s Pharmacopeia,” will cease working with Vice on the show following the third season. He has joined psychedelic pharmaceutical corporation COMPASS Pathways as a chemistry consultant.
COMPASS Pathways’ Psilocybin Patent Questioned By UK Patent Examiner
While COMPASS has issued a response defending the validity of its patents, one of the co-inventors says the patent examiner’s opinion is probably “a valid one.”
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
Featured Stories
DoubleBlind Claims Its Ad Was the ‘First-Ever’ U.S. Psychedelic Destigmatization Campaign — It Wasn’t
DoubleBlind claims its recently-unveiled New York City billboard is a lot of things, except what it actually is: a giant advertisement.
MAPS Canada’s Data Breach Foreshadows Corporadelic Future
As the psychedelic pharmaceutical industry increasingly prioritizes personal data extraction through mobile apps, wearables, and so-called “targeted” medicine, a recent data breach by former MAPS Canada Executive Director Mark Haden provides a warning about some of the possible consequences to the financial incentives of datafication.
Hamilton Morris Hired by Psilocybin Startup COMPASS Pathways, Ends “Hamilton’s Pharmacopeia” On Vice
by Russell Hausfeld , David Nickles
Hamilton Morris, the creator of Vice’s “Hamilton’s Pharmacopeia,” will cease working with Vice on the show following the third season. He has joined psychedelic pharmaceutical corporation COMPASS Pathways as a chemistry consultant.
Nothing found.
Nothing found.
Nothing found.
Nothing found.
Join Our Newsletter
Independent reporting. Critical analysis. In your inbox.
Nothing found.
Nothing found.
Join Our Newsletter
Independent reporting. Critical analysis. In your inbox.
Nothing found.
Nothing found.
Nothing found.
Nothing found.
Series
Nothing found.
A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.
Nothing found.
From Mining to Mushrooms
A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.
Nothing found.
Nothing found.
Nothing found.
Corporadelic
A series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Corporadelic
A series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Nothing found.
Nothing found.
Nothing found.
Nothing found.